No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:57:52.301Z. Latest historical point 2026-02-19. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Praxis Precision Medicines, Inc. (PRAX) stock was $275.87 as of Oct 6, 2026, 1:55 PM EDT, down 2.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +417.4% · 3-year avg +125.4%/yr · 5-year avg -0.2%/yr
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity.
Biotechnology · Boston, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-3.66
Revenue Est.
$130769.00
Last Quarter Results
EPS
$-2.87
vs Estimate
$-3.69
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PRAX | $7.69B | $275.87 | -2.71% | +417.35% | -0.21% | N/A | N/A |
| 2CYTK | $7.61B | $61.19 | -2.41% | +10.01% | +11.24% | +20.95% | vs PRAX |
| 3HQY | $7.61B | $91.02 | -0.58% | +3.33% | +7.00% | +9.16% | vs PRAX |
| 4HNGE | $7.58B | $97.91 | -0.45% | +91.16% | N/A | N/A | vs PRAX |
| 5CAI | $7.93B | $28.07 | -7.63% | -4.35% | N/A | N/A | vs PRAX |
| 6TGTX | $7.95B | $51.93 | -3.67% | +46.58% | +10.75% | +20.46% | vs PRAX |
forward FY estimate
N/A
$0.00
vs Estimate
$1.25M
Consensus Rating
Based on 19 analysts
Average Price Target
$643.58
+133.3% upside
Low
$188.00
Current
$275.87
High
$1201.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-4.07 | $-3.53 | $-3.10 | 12 |
| Quarter ending Dec 2026 | $-4.99 | $-3.99 | $-3.25 | 12 |
| Quarter ending Mar 2027 | $-5.23 | $-3.83 | $-2.43 | 5 |
| Quarter ending Jun 2027 | $-5.36 | $-3.93 | $-2.49 | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-15.16 | $-13.60 | $-12.39 | 14 |
| FY 2027 | $-14.21 | $-9.95 | $-3.72 | 13 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $93959.00 | $130769.00 | $167335.00 | 9 |
| Quarter ending Dec 2026 | $455591.00 | $634071.00 | $811376.00 | 10 |
| Quarter ending Mar 2027 | $21.28M | $29.61M | $37.90M | 9 |
| Quarter ending Jun 2027 | $29.50M | $41.06M | $52.54M | 9 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $708793.00 | $986465.00 | $1.26M | 12 |
| FY 2027 | $168.80M | $348.00M | $479.89M | 14 |
